德琪醫藥(06996.HK)口服XPO1抑制劑「希維奧」於中國多地開出首批處方
德琪醫藥(06996.HK)宣佈,公司旗下首款獲批用於治療復發/難治性多發性骨髓瘤的口服XPO1抑制劑「希維奧」(塞利尼索片),近日正式面向中國多家醫院、互聯網醫院及DTP藥房供藥,並在上海交通大學醫學院附屬瑞金醫院、上海交通大學醫學院附屬仁濟醫院、同濟大學附屬同濟醫院等開出全國首批處方,預計產品5月底前將覆蓋北京、上海、廣東、江蘇、浙江、河南、山東等30個省市及自治區,共600家醫院和105家DTP藥房網絡。
德琪醫藥創始人、董事長兼首席執行官梅建明表示,希維奧在中國的首批處方落地及邁入臨牀應用,極大提升藥物可及性,目前海外商業化團隊正全力提高已獲批國家的患者可及性。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.